The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting for the US government to finalize its decision on ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

The pharma executive also warned that cuts in government funding, along with reduced private sector investment, increases the ...

Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...